Crossmark

Real-world chemotherapy use and survival outcomes in postmenopausal HR+/HER2−breast cancer with low genomic risk (RS ≤ 25): a multicenter cohort study from China

Crossref DOI link: https://doi.org/10.1038/s41598-026-51364-7

Published Online: 2026-05-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hong, Chengye

Wang, Duanduan

Chen, Yongwu

Lin, Songping

Huang, Yidong

Li, Liangqiang

Chen, Debo

Lian, Weibin
Funding

Funding for this research was provided by:

Startup Fund for scientific research, Fujian Medical University (2023QH1301)
License Information

Text and Data Mining valid from 2026-05-02

Version of Record valid from 2026-07-03
More Information

Article History

Received: 14 December 2025

Accepted: 27 April 2026

First Online: 2 May 2026

Competing interests

: The authors have declared no competing interests.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Ethics Committee of Quanzhou First Hospital.

: Formal consent was not required for this type of study.

Document is current

Any future updates will be listed below